Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 4/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.45 |
| ▸ | GPR183 | P32249 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4081838 | 0.93 | LMNA (0.51) | LMNAALDH1A1TP53HPGDSMN1; SMN2 | |
| SCHEMBL4081833 | 0.75 | LMNA (0.47) | LMNAALDH1A1TP53HPGDSMN1; SMN2 | |
| SCHEMBL4081681 | 0.75 | SCD (0.52) | MGLLCHEK2NPY5R | |
| SCHEMBL4096012 | 0.73 | MGLL (0.63) | MGLLCHEK2NPY5R | |
| SCHEMBL5374610 | 0.72 | NPY5R (0.58) | CHEK2NPY5R | |
| SCHEMBL1063378 | 0.71 | GPR183 (0.57) | LMNAALDH1A1TP53HPGDSMN1; SMN2 | |
| SCHEMBL4088468 | 0.71 | NPY5R (0.51) | ALDH1A1CHEK2NPY5R | |
| SCHEMBL31505202 | 0.70 | LMNA (0.57) | LMNAALDH1A1TP53HPGDSMN1; SMN2 | |
| SCHEMBL4085567 | 0.70 | HTR2B (0.56) | TP53HPGDSMN1; SMN2MGLLCHEK2 | |
| SCHEMBL2419558 | 0.70 | MAPT (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6589954-B1 | Indoles, benzimidazoles and benztriazoles which are substituted at the 5 or 6 position with a substituent comprising an aromatic moiety linked through a piperazine ring to said indole, benzimidazole or benztriazole are useful | SCIOS, INC. | 2003-07-08 | — | — | US | claimed |
| US-6340685-B1 | ANTIINFLAMMATORY AGENTS | SCIOS, INC. | 2002-01-22 | — | — | US | claimed |
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | JUNG BIRGIT | 2009-01-15 | — | — | US | disclosed |
| US-20070123516-A1 | Method of treating mucus hypersecretion | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2007-05-31 | — | — | US | disclosed |
| US-20060035893-A1 | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-16 | — | — | US | disclosed |
| US-20030225089-A1 | Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-12-04 | — | — | US | disclosed |
| US-20030220336-A1 | Method of treating mucus hypersecretion | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225089-A1 | Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors | CHRM3, CHRM2, CHRNB1 | LMNA 3362/4885ALDH1A1 3663/4885TP53 4409/4885 |
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BDKRB2, EDNRB, GRK5 | LMNA 3309/4885ALDH1A1 3462/4885TP53 4150/4885 |
| US-20070123516-A1 | Method of treating mucus hypersecretion | MUC1, CFTR, MAPKAPK5 | LMNA 4233/4885ALDH1A1 2978/4885TP53 4484/4885 |
| US-20060035893-A1 | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders | BDKRB2, EDNRB, GRK5 | LMNA 3309/4885ALDH1A1 3462/4885TP53 4150/4885 |
| US-20030220336-A1 | Method of treating mucus hypersecretion | MUC1, CFTR, MAPKAPK5 | LMNA 4233/4885ALDH1A1 2978/4885TP53 4484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.